Phase III results: tiotropium* Respimat® significantly reduces exacerbations in asthma patients still symptomatic despite ICS/LABA treatment
3 September 2012 | By Boehringer Ingelheim
“These results exceeded our expectations..."
List view / Grid view
3 September 2012 | By Boehringer Ingelheim
“These results exceeded our expectations..."
30 August 2012 | By Virgo HEALTH
NextPharma Technologies Holding Limited, is delighted to announce the appointment of two key additions to its executive team...
30 August 2012 | By Novartis
SPARK met its primary endpoint...
30 August 2012 | By Boehringer Ingelheim
European approval for the MycoFLEX® Headspace bottle...
30 August 2012 | By Abbott
Approval extends HUMIRA indication to include moderately active Crohn's Disease...
29 August 2012 | By Novartis
Novartis welcomed its annual International Biotechnology Leadership Camp...
29 August 2012 | By Boehringer Ingelheim
New one-year follow-up results from the global RE-LY AF registry...
28 August 2012 | By Renishaw
Following the success of the Inside Raman seminar last year...
28 August 2012 | By H. Lundbeck A/S
Lundbeck announced that Health Canada has approved Treanda® following the success of the brand in both Europe and the US...
28 August 2012 | By Roche
Daniel O’Day appointed new Head of Roche Pharma– Roland Diggelmann will assume the position Head of Roche Diagnostics...
28 August 2012 | By Novartis
Novartis received approval today from the European Commission for Jakavi®...
AstraZeneca today announced that Pascal Soriot has been appointed as the company’s Chief Executive Officer. Pascal Soriot will take on his new responsibilities and join the AstraZeneca PLC Board as an Executive Director on 1 October 2012.
28 August 2012 | By AstraZeneca
European Commission approves ZINFORO™...
Abbott announced today CE Marking (Conformité Européenne) for a testosterone assay with improved sensitivity and clinical utility. With a simple blood test, the ARCHITECT 2nd Generation Testosterone Assay can accurately measure the wide range of testosterone levels seen in a number of different patient populations and clinical settings.
27 August 2012 | By Gilead Sciences
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved StribildTM...